Efficacy of a complementaryantiinflammatory treatment with erespal in chronic obstructive and non-obstructive bronchitis


Aim. To compare efficacy ofatrovent alone and in combination with erespal in patients with chronic
bronchitis (CB) and chronic obstructive pulmonary disease (COPD).
Material and methods. Of 80 participants of the trial (51 male and 29 female - 63.75 and 36.25%,
respectively) who had CB or COPD, 39 patients (28 with CB and 11 with COPD) received 6-month
combined treatment with erespal (160 mg/day) and atrovent (160 meg/day) and 41 patients (32 with
CB and 9 with COPD) received atrovent monotherapy in the same dosage.
Results. Combined therapy produced positive changes in dyspnea, sputum characteristics and its discharge, cough, monotherapy improved sputum discharge and relieved cough; pulmonary ventilation
improved in both groups especially in those on monotherapy. CB patients showed low cytosis, percentage and absolute count of neutrophils, absolute count of lymphocytes and eosinophils in induced sputum. In С В patients percentage of lymphocytes reduced while count of macrophages went up. Combined treatment including erespal also promoted a significant fall of serum and sputum TNFa and
IL-8 reduction in the sputum.
Conclusion. Erespal+atrovent treatment proved more effective than atrovent alone. It is recommended
for both CB and COPD patients without marked disorders of external respiration function.


  1. Edvard Y., Kato G., Bodinier M. С, Chapelain В. Fenspiride et inflammation en pharmacology experimentale. Eur. Respir. Rev. 1991; 1: 33-40.
  2. Pipy В., Pinelli E., Forgue M. F. et al. Fenspiride inhibits arachidonic acid metabolite production and citolic Ca2+ increase by inflammatory macrophages. Eur. Respir. J. 1992; 5: 237.
  3. Carre Ph., Pipy В., Pinelli E. et al. In vitro effects of fenspiride on the production of free oxygen radicals, prostaglandins and leukotrienes by guinea-pig alveolar macrophages. Eur. Respir. Rev. 1991; 1: 79-85.
  4. Безлепко А. В. Опыт длительного применения фенспирида (эреспала) при лечении больных хроническим обструктивным бронхитом. Пульмонология 2002; 3: 76-82.
  5. Волкова Л. И., Букреева Е. Б., Боярко В. В., Полыца Н. Г Опыт применения фенспирида (эреспала) при обострении хронического бронхита. Клин, фармакол. и тер. 2000; 5 (9): 65-68.
  6. Куницына Ю. Л., Шмелев Е. И. Противовоспалительная терапия больных хронической обструктивной болезнью легких. Пульмонология 2003; 2: 111 - 116.
  7. Овчаренко С. И. Противовоспалительная терапия хронического бронхита. Рус. мед. журн. 2001; 9 (5): 2-24.
  8. Akoun G., Arnaud F., Blanchon F. et al. Effect du fenspiride sur la fonction respiratoire et gazometrie de patients presentant une bronchopathie chronique obstructive stable. Eur. Respir. Rev. 1991; 1: 51-56.
  9. Oliveri D., Del Donno M. Etude de faction du fenspiridi (pneumorel 80 mg) sur la clairance mucociliare chez le bronchitique chronique. J. Intern. Med. 1987; 96: 395-398.
  10. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLB/WHO workshop report. 2001.
  11. Fahy J. V., Liu J., Wong H. et al. Cellular and biochemical analysis of induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am. Rev. Respir. Dis. 1993; 147: 1126-1131.
  12. Lensmar C, Elmberger G., Sandgren P. et al. Leukocyte counts and macrophage phenotypes in induced sputum and bronchoalveolar lavage fluid from normal subjects. Eur. Respir. J. 1998; 12: 595-600.
  13. Rutgers S. R., Timens W., Kaufman H. F. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur. Respir. J. 2000; 15: 109- 115.
  14. Комлев А. Д., Калинина Н. М., Сысоев К. А. и др. Цитокиновый профиль у больных хронической обструктивной болезнью легких. Мед. иммунол. 2002; 4 (1): 87-92.
  15. Bhowmik A., Seemungal Т., Sapsford R. J. et al. Cytokines in induced sputum during exacerbations of chronic obstructive pulmonary disease. Thorax 2000; 55: 114-120.
  16. Keatings V. M., Collins P. D., Scott D. M., Barnes P. G. Differences in interleukin-8 and tumor necrosis factor in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996; 153: 530-534.
  17. Richman-Eisenstadt J. B. Y, Jorens P. G., Hebert С A. et al. Interleukin-8: an important chemoattractant sputum of patients with chronic inflammatory airway diseases. Am. J. Physiol. 1993; 264: L413-L418.
  18. Кетлинский С. А., Калинина Н. М. Цитокины мононуклеарных фагоцитов в регуляции воспаления и иммунитета. Иммунология 1995; 3: 15.
  19. Черешнев В. А., Гусев Е. Ю. Иммунология воспаления: роль цитокинов. Мед. иммунол. 2001; 3 (3): 361-368.
  20. Linden М., Rasmussen J. В., Pitulainen E. et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am. Rev. Respir. Dis. 1993; 148: 1226-1232.
  21. Culpitt S. V., de Matos C, Russell R. E. et al. Effect of theophylline on induced sputum inflammatory induces and neutrophil chemotaxis in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 2002; 165: 1371-1376.
  22. Stockleu R. A., Bauley D. L. Validation of assayes for inflammatory mediators in sputum. Eur. Respir. J. 2000; 15: 779- 781. Y
  23. amamoto C, Yoneda Т., Yoshikawa M. et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505-510.

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies